NOVAVAX INC. overview

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 PR Newswire GAITHERSBURG, Md., April 1, 2024 GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and...

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire GAITHERSBURG, Md., Feb. 29, 2024 GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44 th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston...

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Feb. 28, 2024 Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023 Announced settlement with Gavi related to...

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement PR Newswire GAITHERSBURG, Md. and GENEVA, Feb. 22, 2024 GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a...

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024 PR Newswire GAITHERSBURG, Md., Feb. 20, 2024 GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time...

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire GAITHERSBURG, Md., Jan. 3, 2024 GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42 th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST)...

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan PR Newswire GAITHERSBURG, Md., Dec. 18, 2023 Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid ™ XBB.1.5...

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada PR Newswire GAITHERSBURG, Md., Dec. 5, 2023 Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5...